The BRB Preclinical Repository
for distribution of cytokines, monoclonal antibodies,
reference standards, antisera and other reagents is currently closed.
On-line orders for recombineering reagents and rhIL-2 can still be placed on this website.
- There is no charge for the reagents.
- CYTOKINES ONLY – A handling fee of $160.00 applies and must be paid prior to shipping via credit card (Visa, Master Card) or Purchase Order Request. Instructions will be included in the confirmation letter for your order.
- Reagents can be ordered on the BRB Preclinical Repository ordering page.
SHIPPING INFORMATION FOR RECOMBINEERING REAGENTS
Shipping costs are the responsibility of the recipient.
Once you have placed your order, you will be contacted to arrange payment of the shipping
fee. For CYTOKINES: Only FedEx or World Courier are acceptable courier services.
For RECOMBINEERING REAGENTS: FedEx, UPS or DHL are acceptable couriers.
Please identify courier service and account number on your order form. If required by recipient’s institution,
a PDF file of pre-paid shipping label(s) is acceptable.
NOTE: Required NCI agreements for specific materials are obtained only following
the completion of an on-line request. Email and telephone requests are not accepted.
The BRB is developing clinical and non-clinical supplies of some of the immunomodulating
agents prioritized in the 2007 Immunotherapy Agent Workshop. Agents such as Ad-CCL21,
IL-7, IL-12, IL-15 and MPL will be made available to the community, through a variety
of standard mechanisms.
Limited amounts of the ch14.18 monoclonal antibody currently in Phase III clinical
trials for neuroblastoma are available for investigators interested in identifying
additional disease indications for this antibody. The antibody produced from SP2/0
hybridoma cells targets the disialoganglioside (GD2). Ch14.18 is suitable for use
in ADCC or other assays requiring a humanized antibody. A murine version of the
antibody (14.18G2a) is also available for immunohistochemistry studies. The 1A7 anti-idiotype
antibody that recognizes GD2 antibodies is also available.
For current development status and information on how to obtain one of these special
agents, please contact Dr. Karen Muszynski.